falsefalse

Post-Conference Perspectives: Recent Advances in the Management of Chronic GvHD - Episode 4

Role of Ruxolitinib in Steroid-Refractory Chronic GvHD

,

Dr. Chaudhary introduces data supporting the use of ruxolitinib as a first-line option in patients with steroid-refractory chronic GvHD.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: The Chronic GvHD Landscape: Risk Factors and Diagnosis
    EP. 2: First-line Treatment for Patients with Chronic GvHD
    EP. 3: Defining and Managing Steroid Refractory Chronic GvHD
    Now Viewing
    EP. 4: Role of Ruxolitinib in Steroid-Refractory Chronic GvHD
    EP. 5: Understanding Mechanisms of Action: Ruxolitinib, Ibrutinib, and Belumosudil
    EP. 6: Key Efficacy Data of Ibrutinib and Belumosudil in Steroid-Refractory Chronic GvHD Patients
    EP. 7: Real World Data on the Use of Ruxolitinib and Treatment Selection in chronic GvHD
    EP. 8: Future Directions in Chronic GvHD

    Related Content:

    Post-Conference Perspectives: Recent Advances in the Management of Chronic GvHDOncLive News Network®
    Key Areas of Future Research in Advanced Melanoma
    Where RP1 Plus Nivolumab Could Fit in the Treatment Paradigm for Advanced Melanoma Post–PD-1 Inhibition
    Data for RP1 Plus Nivolumab in Metastatic Melanoma After Prior PD-1 Inhibition
    x